Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Nanoparticles plus Light Results in Dead Tumor Cells

By LabMedica International staff writers
Posted on 05 Sep 2008
Medical physicists have created a novel way to kill tumor cells using nanoparticles and light. More...
The technique employs quantum dots, which are semiconductor nanostructures, 25 billionths of a meter in diameter, which can confine electrons in three dimensions (3D) and emit light when exposed to ultraviolet radiation.

The technique was devised by Dr. Wensha Yang, an instructor in radiation oncology at the University of Virginia (Charlottesville, VA, USA), and colleagues. The investigators realized that quantum dots also emitted light when exposed to megavoltage X-rays, such as those used in cancer radiotherapy. That characteristic, the scientists realized, makes quantum dots an ideal mediator in therapies employing light-activated compounds to treat cancer.

A compound called Photofrin is the only photosensitizer currently approved by the U.S. Food and Drug Administration (FDA). Photofrin is absorbed by cancer cells, upon exposure to light, becomes active, and kills cells. It is currently used to treat specific types of shallowly located tumors, but the researchers realized that combing Photofrin with quantum dots could create an effective method to destroy even deeply seated cancer cells. Upon exposure to high doses of radiation, the dots become luminescent and emit light; that light triggers the cancer-killing activity of the Photofrin. In theory, the process, which so far has been evaluated only in cancer cells grown in culture, could work on tumors located too deep within the body to be reached by an external light source.

To prevent healthy tissues from being affected by the treatment, the toxicity of the quantum dot-Photofrin conjugate is only activated when radiation is applied. Moreover, the area to be treated is targeted with conformal radiation, which is delivered with high precision within the 3D contours of the tumor, with minimal spillover to surrounding healthy tissues. As a result, Dr. Yang said, "the toxicity of the drug is substantially lower in the lower radiation dose area,” outside the boundaries of the tumor. In studies on human lung carcinoma cells, the process resulted in a two to six times lower tumor cell survival compared to radiation alone, but with minimal toxicity to nearby cells.

Dr. Yang described the technique on July 29, 2008, during the 50th annual meeting of the American Association of Physicists in Medicine (AAPM), held, in Houston, TX, USA.

Related Links:
University of Virginia


Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Pipette
Accumax Smart Series
Laboratory Software
ArtelWare
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.